Pfizer Inc. [NYSE: PFE] price surged by 1.32 percent to reach at $0.47. The company report on March 18, 2021 that Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates.
Pyxis expands developmental capabilities with license to two ADC programs and ADC technology platform toolkit developed by Pfizer.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Pyxis Oncology (“Pyxis” or the “Company”) announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for the development and commercialization of two antibody-drug conjugate (ADC) candidates and a license to Pfizer’s ADC technology platform, enabling expansion of its ADC portfolio and further strengthening its developmental capabilities.
A sum of 25380492 shares traded at recent session while its average daily volume was at 33.65M shares. Pfizer Inc. shares reached a high of $36.01 and dropped to a low of $35.36 until finishing in the latest session at $36.00.
The one-year PFE stock forecast points to a potential upside of 12.17. The average equity rating for PFE stock is currently 2.60, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Pfizer Inc. [PFE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PFE shares is $40.99 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PFE stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
DZ Bank have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 04, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts dropped their target price from $43 to $42. The new note on the price target was released on December 16, 2020, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another raise to $40, while Goldman analysts kept a Neutral rating on PFE stock.
The Average True Range (ATR) for Pfizer Inc. is set at 0.55, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 4.82. The Price to Book ratio for the last quarter was 3.07, with the Price to Cash per share for the same quarter was set at 2.18. Price to Free Cash Flow for PFE in the course of the last twelve months was 54.48 with Quick ratio for the last quarter at 1.00.
PFE Stock Performance Analysis:
Pfizer Inc. [PFE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.67. With this latest performance, PFE shares gained by 4.53% in over the last four-week period, additionally plugging by 3.71% over the last 6 months – not to mention a rise of 30.95% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 63.55, with the RSI for the last a single of trading hit 70.79, and the three-weeks RSI is set at 57.40 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 35.32, while it was recorded at 35.78 for the last single week of trading, and 36.48 for the last 200 days.
Insight into Pfizer Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +21.52 and a Gross Margin at +71.21. Pfizer Inc.’s Net Margin is presently recorded at +16.67.
Return on Total Capital for PFE is now 8.14, given the latest momentum, and Return on Invested Capital for the company is 6.93. Return on Equity for this stock inclined to 11.05, with Return on Assets sitting at 4.34. When it comes to the capital structure of this company, Pfizer Inc. [PFE] has a Total Debt to Total Equity ratio set at 65.26. Additionally, PFE Total Debt to Total Capital is recorded at 39.49, with Total Debt to Total Assets ending up at 26.76. Long-Term Debt to Equity for the company is recorded at 60.48, with the Long-Term Debt to Total Capital now at 36.60.
Reflecting on the efficiency of the workforce at the company, Pfizer Inc. [PFE] managed to generate an average of $88,981 per employee. Receivables Turnover for the company is 5.03 with a Total Asset Turnover recorded at a value of 0.26.Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.40.
PFE Stock EPS
With the latest financial reports released by the company, Pfizer Inc. posted 0.8/share EPS, while the average EPS was predicted by analysts to be reported at 0.73/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to 10.07%.
Pfizer Inc. [PFE] Insider Position Details
There are presently around $133,230 million, or 67.60% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 447,958,747, which is approximately -0.691% of the company’s market cap and around 0.05% of the total institutional ownership; BLACKROCK INC., holding 396,973,512 shares of the stock with an approximate value of $14.29 billion in PFE stocks shares; and STATE STREET CORP, currently with $10.06 billion in PFE stock with ownership of nearly -3.29% of the company’s market capitalization.
Positions in Pfizer Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 1,553 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 127,106,988 shares. Additionally, 1,049 investors decreased positions by around 251,267,943 shares, while 186 investors held positions by with 3,322,454,750 shares. The mentioned changes placed institutional holdings at 3,700,829,681 shares, according to the latest SEC report filing. PFE stock had 279 new institutional investments in for a total of 17,629,446 shares, while 114 institutional investors sold positions of 22,568,463 shares during the same period.